

Relation of Circulating Liver Transaminase Concentrations to Atrial Fibrillation

American Journal of Cardiology

111, 219-224

DOI: [10.1016/j.amjcard.2012.09.021](https://doi.org/10.1016/j.amjcard.2012.09.021)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intermittent manifestation of pre-excitation syndrome: "This door is not open 24/7". International Journal of Cardiology, 2013, 168, 2938-2940.	0.8	2
2	The pivotal roles of risk factors for incident atrial fibrillation: interweaving pieces of puzzle. International Journal of Cardiology, 2013, 168, 2937-2938.	0.8	6
3	Atrial fibrillation in patients with acute coronary syndromes. International Journal of Cardiology, 2013, 168, 5049.	0.8	3
4	Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with Type 2 diabetes. Clinical Science, 2013, 125, 301-310.	1.8	107
5	eComment. Atrial fibrillation in patients undergoing thoracic surgery. Interactive Cardiovascular and Thoracic Surgery, 2013, 17, 686-687.	0.5	0
6	Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. PLoS ONE, 2013, 8, e57183.	1.1	153
7	Hemostatic markers can be pivotal roles of risk factors for new-onset atrial fibrillation. Platelets, 2014, 25, 554-555.	1.1	12
8	Inflammatory status as a major role of risk factor for atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2014, 37, 540-541.	1.0	4
9	Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart, 2014, 100, 1511-1516.	1.2	83
10	Risk factors for new-onset atrial fibrillation. International Journal of Cardiology, 2014, 171, e46.	0.8	3
11	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 1724.	1.4	207
12	Prevalence of Atrial Fibrillation and Relation to Echocardiographic Parameters in a Healthy Asymptomatic Rural Korean Population. Journal of Korean Medical Science, 2015, 30, 1078.	1.1	12
13	Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS ONE, 2015, 10, e0142937.	1.1	112
14	NAFLD: A multisystem disease. Journal of Hepatology, 2015, 62, S47-S64.	1.8	2,037
15	Non-Alcoholic Fatty Liver Disease (NAFLD): A New Cardiovascular Risk Factor. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2015, 22, 209-216.	0.3	0
16	Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). International Journal of Cardiology, 2015, 201, 113-118.	0.8	37
18	Ambulatory Blood Pressure Characteristics and Long-Term Risk for Atrial Fibrillation. American Journal of Hypertension, 2017, 30, 264-270.	1.0	13
19	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 1246-1267.	1.1	99

#	ARTICLE	IF	CITATIONS
20	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. <i>Medicine (United States)</i> , 2016, 95, e2760.	0.4	17
21	Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population. <i>Atherosclerosis</i> , 2016, 245, 123-131.	0.4	42
22	Doppler Tissue Evaluation of Atrial Conduction Properties in Patients With Non-alcoholic Fatty-liver Disease. <i>Ultrasonic Imaging</i> , 2016, 38, 225-235.	1.4	27
23	Non-alcoholic fatty liver disease and risk of cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1136-1150.	1.5	190
24	Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	37
25	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2017, 29, 141-148.	0.1	4
26	Liver enzymes are not directly involved in atrial fibrillation: a prospective cohort study. <i>European Journal of Clinical Investigation</i> , 2017, 47, 583-590.	1.7	5
27	Enfermedad del h�gado graso no alcoh�lico, asociaci�n con la enfermedad cardiovascular y tratamiento (I). Enfermedad del h�gado graso no alcoh�lico y su asociaci�n con la enfermedad cardiovascular. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2017, 29, 141-148.	0.4	9
28	Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis. <i>Postepy W Kardiologii Interwencyjnej</i> , 2017, 3, 250-257.	0.1	4
29	Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation?. <i>Digestive and Liver Disease</i> , 2018, 50, 626-628.	0.4	4
30	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 425-439.	8.2	207
31	Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	24
32	NAFLD and cardiovascular disease. <i>Porto Biomedical Journal</i> , 2018, 3, e2.	0.4	7
33	The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. <i>Annals of Medicine</i> , 2018, 50, 371-380.	1.5	20
34	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
35	Association between non�alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta�analysis. <i>Liver International</i> , 2019, 39, 758-769.	1.9	75
36	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2215.	1.8	42
37	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 818-820.	1.9	0

#	ARTICLE	IF	CITATIONS
38	Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481983223.	1.4	15
39	Nonalcoholic Fatty Liver Disease and the Heart. <i>Journal of the American College of Cardiology</i> , 2019, 73, 948-963.	1.2	259
40	Liver Enzymes and the Risk of Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 865-870.	0.3	3
41	Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 933-940.	1.9	17
42	Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. <i>Echocardiography</i> , 2019, 36, 249-256.	0.3	11
43	Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 10-30.	0.5	50
44	Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults. <i>Liver International</i> , 2020, 40, 338-346.	1.9	18
45	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093380.	0.7	12
46	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	2.0	121
47	Cardiac abnormalities in patients with nonalcoholic fatty liver disease. <i>Herz</i> , 2021, 46, 158-163.	0.4	3
48	Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. <i>Scientific Reports</i> , 2021, 11, 3737.	1.6	17
49	New biomarkers from multiomics approaches: improving risk prediction of atrial fibrillation. <i>Cardiovascular Research</i> , 2021, 117, 1632-1644.	1.8	12
50	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , 2021, 41, 235-247.	1.8	4
51	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. <i>Circulation Research</i> , 2021, 128, 1747-1765.	2.0	49
52	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <i>Clinical Science</i> , 2020, 134, 1775-1799.	1.8	25
53	Metabolomics and Incidence of Atrial Fibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. <i>PLoS ONE</i> , 2015, 10, e0142610.	1.1	29
54	Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-8.	0.7	47
55	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. <i>European Cardiology Review</i> , 2014, 9, 10.	0.7	8

#	ARTICLE	IF	CITATIONS
56	Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. <i>Oncotarget</i> , 2017, 8, 60673-60683.	0.8	14
57	Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Yonsei Medical Journal</i> , 2020, 61, 860.	0.9	14
58	Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2017, 9, e1142.	0.2	12
59	Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. <i>Cureus</i> , 2017, 9, e1165.	0.2	11
61	The features of autonomic disorders and ischemic myocardial changes in patients with stable angina pectoris associated with nonalcoholic fatty liver disease. <i>ScienceRise: Medical Science</i> , 2016, .	0.0	0
62	Evaluation of effectiveness of monotherapy with capicor and glutargin in patients with permanent atrial fibrillation and comorbid pathology of the liver during long-term warfarin therapy. <i>Bukovinian Medical Herald</i> , 2016, 20, 57-62.	0.1	0
63	Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. <i>Annals of Gastroenterology</i> , 2020, 33, 603-614.	0.4	13
64	Nonalcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 530-535.	0.1	1
65	Part 1: Disease of the Heart and Liver. <i>Cardiology in Review</i> , 2022, 30, 111-122.	0.6	2
66	Non-alcoholic fatty liver disease and cardiovascular diseases: features of the comorbid course. <i>LÄ-ki UkraÄni</i> , 2020, .	0.0	2
67	A Novel Predictive Model of Recurrence after Surgical Ablation of Valvular Atrial Fibrillation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
68	Determinants of Use of Long-term Continuous Electrocardiographic Monitoring for Acute Ischemic Stroke Patients without Atrial Fibrillation at Baseline. <i>Current Neurovascular Research</i> , 2020, 17, 224-231.	0.4	0
69	Pivotal roles of risk factors for incident atrial fibrillation in patients with newly diagnosed hyperthyroidism. <i>Journal of Geriatric Cardiology</i> , 2013, 10, 119-20.	0.2	3
70	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 216-253.	0.2	19
71	Further Advances in Atrial Fibrillation Research: A Metabolomic Perspective. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 3201.	1.3	0
73	Non-Alcoholic Fatty Liver Disease and other Non-Communicable Diseases: Time for an Integrated Approach. <i>Indian Journal of Community Health</i> , 2022, 34, 03-10.	0.1	1
74	Association between serum apolipoprotein B and atrial fibrillation: a caseâ€“control study. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
75	Association Between Serum Aminotransferases and Risk of New-Onset Cardiometabolic Disease in a Healthy Chinese Population: A Cohort Study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3

#	ARTICLE	IF	CITATIONS
76	Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation. BMC Medical Genomics, 2022, 15, .	0.7	4
77	High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Frontiers in Endocrinology, 0, 13, .	1.5	6
79	The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Frontiers in Endocrinology, 0, 13, .	1.5	12
80	Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction. ESC Heart Failure, 2023, 10, 1771-1780.	1.4	5
81	Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Current Problems in Cardiology, 2023, 48, 101643.	1.1	8
82	Evaluation of New Potential Inflammatory Markers in Patients with Nonvalvular Atrial Fibrillation. International Journal of Molecular Sciences, 2023, 24, 3326.	1.8	3
83	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	1